International review of psychiatry (Abingdon, England)Aug 14, 2018

Using classic psychedelics to help with cancer-related mental health distress

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 28, 2026

Abstract

A total of 445 participants were involved in 10 clinical trials examining psychedelic treatments for cancer-related psychiatric distress.

Early-phase studies from 1964 to 1980 suggested that psychedelic therapy, mainly with LSD, may alleviate cancer-related depression, anxiety, and fear of death.
Recent randomized controlled trials from 2011 to 2016 primarily utilized psilocybin and indicated that psychedelic-assisted therapy could lead to rapid and lasting improvements in psychological and existential distress among cancer patients.
The majority of patients in these trials had advanced or terminal cancer diagnoses.
The research indicates a renewed interest in psychedelic-assisted therapy for addressing psychiatric issues in cancer patients.

Simplified

Cancer is highly prevalent and one of the leading causes of global morbidity and mortality. Psychological and existential suffering is common in cancer patients, associated with poor psychiatric and medical outcomes. Promising early-phase clinical research (1960s to early 1970s) suggested a therapeutic signal for serotoninergic psychedelics (e.g. psilocybin, LSD) in treating cancer-related psychiatric distress. After several decades of quiescence, research on psychedelic-assisted therapy to treat psychiatric disorders in cancer patients has resumed within the last 2 decades in the US and Europe. This review article is based on a systematic search of clinical trials from 1960-2018 researching the therapeutic use of psychedelic treatment in patients with serious or terminal illnesses and related psychiatric illness. The search found 10 eligible clinical trials, with a total of 445 participants, with the vast majority of the patients having advanced or terminal cancer diagnoses. Six open label trials, published between 1964 and 1980 ( = 341), suggested that psychedelic therapy (mostly with LSD) may improve cancer-related depression, anxiety, and fear of death. Four RCTs trials were published between 2011 and 2016 ( = 104), mostly with psilocybin treatment ( = 92), and demonstrated that psychedelic-assisted treatment can produce rapid, robust, and sustained improvements in cancer-related psychological and existential distress. n n n

Full Text

Full text is available at the source.

View Full Text ↗

Using classic psychedelics to help with cancer-related mental health distress

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief